# | Title | Journal | Year | Citations |
---|
1 | Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma | New England Journal of Medicine | 2015 | 6,773 |
2 | A cell cycle regulator potentially involved in genesis of many tumor types | Science | 1994 | 2,664 |
3 | International uniform response criteria for multiple myeloma | Leukemia | 2006 | 2,332 |
4 | The management of respiratory motion in radiation oncology report of AAPM Task Group 76a) | Medical Physics | 2006 | 1,829 |
5 | Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma | New England Journal of Medicine | 2017 | 1,752 |
6 | Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study | Lancet Oncology, The | 2012 | 1,182 |
7 | Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy | New England Journal of Medicine | 2016 | 1,140 |
8 | Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial | Lancet Oncology, The | 2015 | 1,093 |
9 | Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial | Lancet Oncology, The | 2018 | 1,089 |
10 | Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study | Lancet Oncology, The | 2011 | 1,028 |
11 | Cancer-associated cachexia | Nature Reviews Disease Primers | 2018 | 908 |
12 | Adjuvant Docetaxel for Node-Positive Breast Cancer | New England Journal of Medicine | 2005 | 892 |
13 | Software for molecular docking: a review | Biophysical Reviews | 2017 | 880 |
14 | Sarcopenia as a Determinant of Chemotherapy Toxicity and Time to Tumor Progression in Metastatic Breast Cancer Patients Receiving Capecitabine Treatment | Clinical Cancer Research | 2009 | 872 |
15 | Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma | Leukemia | 2008 | 787 |
16 | Fluorouracil, Mitomycin, and Radiotherapy vs Fluorouracil, Cisplatin, and Radiotherapy for Carcinoma of the Anal Canal | JAMA - Journal of the American Medical Association | 2008 | 743 |
17 | Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial | Lancet, The | 2016 | 724 |
18 | Localization of an ataxia-telangiectasia gene to chromosome 11q22–23 | Nature | 1988 | 677 |
19 | Enzymatic Activity Associated with Class II HDACs Is Dependent on a Multiprotein Complex Containing HDAC3 and SMRT/N-CoR | Molecular Cell | 2002 | 663 |
20 | Muscle Wasting Is Associated With Mortality in Patients With Cirrhosis | Clinical Gastroenterology and Hepatology | 2012 | 659 |
21 | Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy | European Urology | 2017 | 638 |
22 | Recommendations for Radioembolization of Hepatic Malignancies Using Yttrium-90 Microsphere Brachytherapy: A Consensus Panel Report from the Radioembolization Brachytherapy Oncology Consortium | International Journal of Radiation Oncology Biology Physics | 2007 | 625 |
23 | Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report | Blood | 2015 | 586 |
24 | Obinutuzumab for the First-Line Treatment of Follicular Lymphoma | New England Journal of Medicine | 2017 | 575 |
25 | Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study | Lancet Oncology, The | 2016 | 533 |
26 | Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2 | Journal of Clinical Oncology | 2010 | 498 |
27 | Long-Term Update of US GI Intergroup RTOG 98-11 Phase III Trial for Anal Carcinoma: Survival, Relapse, and Colostomy Failure With Concurrent Chemoradiation Involving Fluorouracil/Mitomycin Versus Fluorouracil/Cisplatin | Journal of Clinical Oncology | 2012 | 480 |
28 | Severe muscle depletion in patients on the liver transplant wait list: Its prevalence and independent prognostic value | Liver Transplantation | 2012 | 460 |
29 | Loss of imprinting of IGF2 is linked to reduced expression and abnormal methylation of H19 in Wilms' tumour | Nature Genetics | 1994 | 454 |
30 | Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial | Lancet Oncology, The | 2017 | 451 |
31 | A convolution method of calculating dose for 15-MV x rays | Medical Physics | 1985 | 450 |
32 | Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial | Lancet Oncology, The | 2014 | 446 |
33 | Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma | Journal of Clinical Oncology | 2022 | 446 |
34 | AP Endonuclease-Independent DNA Base Excision Repair in Human Cells | Molecular Cell | 2004 | 434 |
35 | Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial | Journal of Clinical Oncology | 2018 | 431 |
36 | Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial | Lancet Oncology, The | 2017 | 428 |
37 | Randomized Phase IIB Trial of BLP25 Liposome Vaccine in Stage IIIB and IV Non–Small-Cell Lung Cancer | Journal of Clinical Oncology | 2005 | 415 |
38 | Phase III studies of single-agent docetaxel in patients with metastatic breast cancer who have progressed despite previous chemotherapy regimens: preliminary results | Seminars in Oncology | 1998 | 399 |
39 | Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases | Annals of Oncology | 2018 | 388 |
40 | Defective DNA single-strand break repair in spinocerebellar ataxia with axonal neuropathy-1 | Nature | 2005 | 382 |
41 | Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation | The Hematology Journal | 2003 | 374 |
42 | Mitotic Transcription Repression in Vivo in the Absence of Nucleosomal Chromatin Condensation | Journal of Cell Biology | 2000 | 372 |
43 | Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis | Journal of Cachexia, Sarcopenia and Muscle | 2016 | 372 |
44 | Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. | Journal of Clinical Oncology | 1996 | 359 |
45 | The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix | | 1999 | 359 |
46 | Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12 | Journal of Clinical Oncology | 2014 | 358 |
47 | Randomized phase II trial of gemcitabine–cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer | Annals of Oncology | 2004 | 351 |
48 | Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma | Blood | 2016 | 347 |
49 | The relationship between waiting time for radiotherapy and clinical outcomes: A systematic review of the literature | Radiotherapy and Oncology | 2008 | 334 |
50 | Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer | Journal of Clinical Oncology | 2021 | 329 |